{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["48(11)"],"submitter":["Sinn M"],"pubmed_abstract":["

Introduction: Cancer-associated venous thromboembolism (CAT) is a frequent and medical relevant problem. Guidelines recommend treatment with low molecular weight heparins (LMWH) or direct oral factor-Xa inhibitors as rivaroxaban for ≥3 months. Patient's preference and convenience is an important factor to guide treatment decision and to support treatment adherence. No data are available so far about patient-reported outcome in CAT.

Methods

CONKO-011/AIO-SUP-0115/ass. was an open-label, prospective, multicenter German phase III trial for cancer patients with newly diagnosed venous thromboembolism (VTE) randomized to rivaroxaban (Riva) or site-specific LMWH. Primary endpoint was patient-reported treatment satisfaction, measured by the Anti-Clot Treatment Scale (ACTS). The 12-item A"],"journal":["Oncology research and treatment"],"pagination":["685-695"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12237281"],"repository":["biostudies-literature"],"pubmed_title":["CONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism."],"pmcid":["PMC12237281"],"pubmed_authors":["Pelzer U","Striefler JK","Riess H","Hellmann M","Roderburg C","Trappe RU","Sudhoff T","Schlenska-Lange A","Wernecke KD","Mohamed O","Semrau S","Lohneis A","Heinz J","Ettrich TJ","Krziwanie A","Sinn M","Christoph DC"],"additional_accession":[]},"is_claimable":false,"name":"CONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism.","description":"

Introduction: Cancer-associated venous thromboembolism (CAT) is a frequent and medical relevant problem. Guidelines recommend treatment with low molecular weight heparins (LMWH) or direct oral factor-Xa inhibitors as rivaroxaban for ≥3 months. Patient's preference and convenience is an important factor to guide treatment decision and to support treatment adherence. No data are available so far about patient-reported outcome in CAT.

Methods

CONKO-011/AIO-SUP-0115/ass. was an open-label, prospective, multicenter German phase III trial for cancer patients with newly diagnosed venous thromboembolism (VTE) randomized to rivaroxaban (Riva) or site-specific LMWH. Primary endpoint was patient-reported treatment satisfaction, measured by the Anti-Clot Treatment Scale (ACTS). The 12-item A","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-06T17:23:53.198Z","creation":"2026-06-03T03:10:16.292Z"},"accession":"S-EPMC12237281","cross_references":{"pubmed":["40418924"],"doi":["10.1159/000545976"]}}